SEHK:867Pharmaceuticals
AI Drug Discovery Push And New Kidney Drug Trial Could Be A Game Changer For China Medical System Holdings (SEHK:867)
In early February 2026, Insilico Medicine announced a partnership with China Medical System Holdings to apply its AI platform to at least two co-developed drug discovery programs, while CMS separately received Chinese regulatory approval to begin human clinical trials of its self-developed complement factor B inhibitor CMS-D017 for complement-mediated kidney diseases.
Together, the AI-enabled collaboration and first-in-human trial clearance highlight CMS’s push to build an innovative...